Inappropriate tuberculosis treatment regimens in chinese tuberculosis hospitals

Clinical Infectious Diseases

Volumn 52, Issue 7, 2011, Pages

  Xue He, Guang ^a,e   Van Den Hof, Susan ^e,f   Van Der Werf, Marieke J ^e,f   Guo, Hui ^a   Hu, Yuan Lian ^b   Fan, Ji Huan ^d   Zhang, Wei Min ^a   Tostado, Christopher P ^c   Borgdorff, Martien W ^e  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Fengtai Center for Disease Control and Prevention   (China)

^c TSINGHUA UNIVERSITY   (China)

^d HENAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHILD; CHINESE; CONTROLLED STUDY; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; GUIDELINE ADHERENCE; HEALTH SERVICES RESEARCH; HOSPITALS, CHRONIC DISEASE; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS; TUBERCULOSIS; YOUNG ADULT;

EID: 79953731154     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir075     Document Type: Article

References (12)

1. World Health Organization. Treatment of tuberculosis: guidelines- fourth edition.-WHO/HTM/TB/2009.420. Geneva, Switzerland: World Health Organization, 2009.
2. World Health Organization. Guideline for the programmatic management of drug-resistant tuberculosis.Emergency update 2008. WHO/HTM/TB/ 2008.402. Geneva, Switzerland: World Health Organization, 2008.
3. Ministry of Health of the People's Republic of China. Nationwide anti-tuberculosis drug resistant baseline surveillance in China (2007-2008). Beijing, China: People's Public Health Press, 2010.
4. World Health Organization. The global MDR-TB and XDR-TB response plan. WHO/HTM/TB/2007.387. Geneva, Switzerland: World Health Organization, 2007.
5. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13:380-387. (Pubitemid 46348124)
6. World Health Organization. Countries that had reported at least one XDR-TB case by end March 2009. Available at: http://www.who.int/tb/ challenges/xdr/xdr-map-mar09.pdf. Accessed 17 November 2009.
7. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrugresistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
8. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. Geneva, Switzerland: World Health Organization, 2009.
9. He GX, Van den Hof S, Borgdorff MW, et al. Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: a sit-uational analysis. Int J Tuberc Lung Dis 2010; 14:884-889.
10. World Health Organization. Implementing the WHO Stop TB Strategy: a handbook for national tuberculosis control programmes. Geneva, Switzerland: World Health Organization, 2008.
11. Chinese Center for Disease Control and Prevention. Disease Control Bureau and Medical Administrative Department of Ministry of Health of the People's Republic of China.National Tuberculosis Control Programme Guideline in China (2008). Beijing, China: Peking, Union Medical College Press, 2009.
12. He GX, Zhao YL, Jiang GL, et al. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC InfectDisDi 2008; 8:166 doi: 10.1186/1471-2334-8-166. Available at: http://www.biomedcen-tral.com/1471-2334/ 8/166. Accessed 11 December 2008.